Aegerion Pharmaceuticals, Inc. 4
4 · Aegerion Pharmaceuticals, Inc. · Filed Dec 1, 2016
Insider Transaction Report
Form 4
Broadfin Healthcare Master Fund Ltd
10% Owner
Transactions
- Disposition to Issuer
Common Stock, $0.001 par value
2016-11-29−4,361,291→ 0 total
Footnotes (2)
- [F1]Disposed of in exchange for 4,472,939 common shares of Novelion Therapeutics Inc ("Novelion") pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective November 29, 2016. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc."
- [F2]The securities are held in the account of Broadfin Healthcare Master Fund, Ltd., a private investment fund managed by Broadfin Capital, LLC and may be deemed to be beneficially owned by Kevin Kotler, managing member of Broadfin Capital, LLC. Each of Broadfin Capital, LLC, Broadfin Healthcare Master Fund, Ltd. and Kevin Kotler disclaim beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and affirmatively disclaim being a "group" for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.